Arcutis Biotherapeutics recently reported positive topline results from its INTEGUMENT-INFANT Phase 2 trial, showing that ZORYVE cream 0.05% improved disease severity and was well tolerated in 101 ...

During the cold winter months, many people notice their skin’s condition worsens. Dry air and indoor heating can exacerbate symptoms of eczema, or atopic dermatitis. This leads to dry, cracked ...

Topical pumecitinib 3% gel shows strong efficacy and good tolerability in mild-to-moderate atopic dermatitis. Explore the ...

INDICATIONS ZORYVE cream, 0.05%, is indicated for topical treatment of mild to moderate atopic dermatitis in pediatric patients 2 to 5 years of age. ZORYVE cream, 0.15%, is indicated for topical ...

Arcutis Biotherapeutics and Kowa Pharmaceuticals are cutting ties on their U.S. marketing partnership around Arcutis’ Zoryve ...

We spoke to dermatologists and conducted research to select the best lotions for eczema, including picks from Eucerin, Gold ...

Organon (NYSE: OGN), a global independent healthcare company with a focus on women’s health, will present results from a sub-analysis of pooled data from the Phase 3 ADORING 1 and ADORING 2 pivotal ...

Add Yahoo as a preferred source to see more of our stories on Google. The double-blind Incyte has announced results from the Phase IIIb TRuE-AD4 trial of Opzelura (ruxolitinib cream) for adults with ...

Incyte (Nasdaq:INCY) today announced new data from the Phase 3b TRuE-AD4 study evaluating the efficacy and safety of Opzelura ® (ruxolitinib cream) in adults with moderate atopic dermatitis (AD) who ...

New data from Phase 3 studies show once-daily ZORYVE cream helped reduce sleep disruptions in individuals with atopic dermatitis aged =2 years New long-term data demonstrate that ZORYVE cream was well ...